Two lung adenocarcinoma patients with multiple brain metastasis treated with Gefitinib and surviving more than 2 years

Case 1 is a 78-year-old woman in whom lung adenocarcinoma with multiple brain metastasis (cT2N3M1, stage IV) was diagnosed. She was treated with Gefitinib alone. Her lung tumor and metastatic brain lesions decreased 6 months after the start of therapy. She has no recurrence and is still alive with a...

Full description

Saved in:
Bibliographic Details
Published inNihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society Vol. 44; no. 9; p. 653
Main Authors Matsuyama, Wataru, Yamamoto, Masuki, Machida, Kentarou, Mitsuyama, Hideo, Watanabe, Masaki, Higashimoto, Ikkou, Osame, Mitsuhiro, Arimura, Kimiyoshi
Format Journal Article
LanguageJapanese
Published Japan 01.09.2006
Subjects
Adenocarcinoma, Papillary - drug therapy
Adenocarcinoma, Papillary - secondary
Aged
Aged, 80 and over
Antineoplastic Agents - therapeutic use
Bone Neoplasms - radiotherapy
Bone Neoplasms - secondary
Brain Neoplasms - drug therapy
Brain Neoplasms - secondary
Drug Administration Schedule
Female
Humans
Lung Neoplasms - drug therapy
Lung Neoplasms - pathology
Quinazolines - therapeutic use
Radiotherapy Dosage
Survivors
Online AccessGet more information

Cover

More Information
Summary:Case 1 is a 78-year-old woman in whom lung adenocarcinoma with multiple brain metastasis (cT2N3M1, stage IV) was diagnosed. She was treated with Gefitinib alone. Her lung tumor and metastatic brain lesions decreased 6 months after the start of therapy. She has no recurrence and is still alive with a good performance status after 25 months. Case 2 is an 80-year-old woman in whom lung adenocarcinoma with multiple brain (cT2N3M1, stage IV) was diagnosed. She was also treated with Gefitinib alone and her lung tumor and metastatic brain becomes improved 6 months after the start of therapy. She maintained a good performance status for more than 2 years (29 months). However, 29 months after beginning treatment, she had recurrence in bone and died 2 months later, 31 months after the start of therapy. The prognosis of non-small cell lung cancer with multiple brain metastasis is very poor and the efficacy of chemotherapy for the treatment of multiple brain metastases is limited, and longterm survival remains disappointing. We report two lung adenocarcinoma patients with multiple brain metastasis who survived more than 2 years by treatment with Gefitinib alone.
ISSN:1343-3490